スマートピル市場 – 2030年までの世界予測

Report Overview

The global smart pills market is experiencing significant growth in 2024, driven by the technological advancements in capsule endoscopy and the growing demand for non-invasive diagnostic monitoring devices. The market is projected to reach reach USD 1.30 billion by 2030 from USD 0.69 billion in 2024, at a CAGR of 11.2% during the forecast period.

世界のスマートピル市場は、カプセル内視鏡の技術的進歩と非侵襲性診断モニタリング機器の需要増加により、2024年に大幅な成長を遂げる見込みです。市場は、予測期間中に11.2%のCAGRで成長し、2024年の6億9,000万米ドルから2030年には13億米ドルに達すると予測されています。

According to the American Cancer Society (ACS), in 2024, there were 1,52,810 new cases of colorectal cancer (CRC) comprising, 81,540 will be in men and 71,270 in women. Additionally, 1,06,590 of the cases will be colon cancer, while 46,220 will be rectal cancer. CRC remains the second leading cause of cancer-related deaths in the US with an estimated 53,010 deaths in 2024, showing a slight increase from last year’s projected 52,550. Thus, the high incidence of colon cancer are expected to increase the demand for capsule endoscopes for colon cancer screening.

アメリカがん協会（ACS）によると、2024年には大腸がん（CRC）の新規症例が152,810件発生し、そのうち81,540件が男性、71,270件が女性となる見込みです。また、症例のうち106,590件が結腸がん、46,220件が直腸がんとなります。CRCは米国におけるがん関連死の第2位の原因であり、2024年には53,010人が死亡すると推定され、昨年の予測52,550人からわずかに増加しています。したがって、結腸がんの発生率が高いことから、結腸がん検査用のカプセル内視鏡の需要が高まると予想されます。

“The small bowel tumor segment is projected to grow at the highest CAGR during the forecast period.”

Based on disease indication, the market for smart pills is divided into segments for crohn’s disease, small bowel tumors, occult GI bleeding, celiac disease, and other disease indications. The small bowel tumor is expected to grow at the highest CAGR during the forecast period due to factors, such as advancements in sensor technology, growing emphasis on patient convenience, rising need for early tumor diagnosis and proper treatment that are expected to drive the adoption of smart pills in the coming years.

“The large intestine accounted for the second largest share of the market during the forecast period in 2023, by target area. “

By target area, the smart pills market is broadly segmented into, small intestine, large intestine, esophagus, and stomach. In 2023, the large intestine target area accounted for the second largest share of smart pills market. Factors such as rising cases of colorectal cancer and requirement for applicable screening, diagnosis, and examining of inflammatory bowel diseases and other gastrointestinal diseases. The growing cases of colorectal cancer & colon cancer have contributed to the rising adoption of smart pills in large intestine as smart pills can reach areas of the colon that may be difficult to visualize with traditional methods.

By region, Europe hold the second largest share of the smart pills market in 2023

Europe accounted for the second largest share of the smart pills market in 2023. Factors such as increase in ageing population and improved utilization of capsule endoscopy for gastrointestinal (GI) bleeding are driving the European smart pills market. According to the guidelines of the European Society of Gastrointestinal Endoscopy (ESGE), small-bowel video capsule endoscopy is recommended as the initial examination for patients with unclear gastrointestinal bleeding. The endorsement of capsule endoscopy by the ESGE guidelines specifies a uniform approach for healthcare professionals, improving the quality of care provided to patients. As a result, the expanding demand for smart pills and other related technologies is driven by the growing use of capsule endoscopy for GI bleeding.

The break up of the profile of primary participants in the smart pills market:

• By Company Type: Tier 1- 40%, Tier 2- 35%, and Tier 25%
• By Designation: C-level Executives- 50%, Directors- 40% , and Others- 10%.
• By Region: North America- 45%, Europe- 30%, Asia Pacific- 20%, Latin America- 3%, and Middle East & Africa- 2%.

Key players in the Smart pills market

The key players operating in the smart pills market include Medtronic  (US), Olympus Corporation (Japan), CapsoVision,Inc. (US), IntroMedic (South Korea), ANX Robotics (US), Shenzhen Jifu Medical Technology Co., Ltd. (China), JINSHAN Science & Technology (Group)   (China), etectrx (US), Check-Cap (Israel), BodyCap (France) ,and Shangxian Minimal Invasive Inc (China).

Research Coverage:

The report analyzes the smart pills market and aims at estimating the market size and future growth potential of this market based on various segments such as application (capsule endoscopy,patient monitoring, and targeted drug delivery), target area (small intestine,large intestine, esophagus & stomach), disease indication (crohn’s disease, occult GI bleeding, small bowel tumor, celiac disease, & other disease conditions), end user (hospitals, diagnostic centers, outpatient settings, & other end users), and region (North America, Europe, Asia Pacific, Latin America, and Middle East and Africa). The report also includes a product portfolio matrix of various smart pills products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, service offerings, and key market strategies.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:

• Analysis of key drivers (rising demand for noninvasive diagnostic monitoring devices, technological advancements in capsule endoscopy, increasing incidence of colon cancer), restraints (high costs & technical limitations associated with accuracy of smart pills), opportunities (continuous innovation in sensor technology, wireless communication and rising need for rapid drug delivery development) and challenges (patient privacy concerns, shortage of skilled personnel).
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the smart pills market
• Market Development: Comprehensive information about lucrative markets – the report analyses the smart pills market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the smart pills market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of Medtronic (US), Olympus Corporation (Japan), CapsoVision,Inc. (US), IntroMedic (South Korea), ANX Robotics (US), Shenzhen jifu Medical Technology Co., Ltd. (China), JINSHAN Science & Technology (Group)   (China), etectrx (US), Check-Cap (Israel), BodyCap (France) , and Shangxian Minimal Invasive Inc (China) in the smart pills market.

Table of Contents

1               INTRODUCTION              25

1.1           STUDY OBJECTIVES       25

1.2           MARKET DEFINITION   25

1.3           STUDY SCOPE   26

1.3.1        MARKET SEGMENTATION & GEOGRAPHICAL SPREAD                 26

1.3.2        INCLUSIONS & EXCLUSIONS       27

1.3.3        YEARS CONSIDERED      28

1.3.4        CURRENCY CONSIDERED            28

1.4           STAKEHOLDERS               28

1.5           SUMMARY OF CHANGES               29

2               RESEARCH METHODOLOGY       30

2.1           RESEARCH DATA              30

2.1.1        SECONDARY DATA          30

2.1.1.1    Key sources of secondary data            31

2.1.1.2    Key data from secondary sources       31

2.1.2        PRIMARY DATA 32

2.1.2.1    Objectives of primary research           32

2.1.2.2    Key data from primary sources           33

2.1.2.3    Insights from primary experts             33

2.1.3        MARKET SIZE ESTIMATION         34

2.1.3.1    Supply-side analysis             34

2.1.3.2    Bottom-up approach (demand-side analysis)  35

2.1.3.3    Top-down approach (parent market assessment)           36

2.2           DATA TRIANGULATION                40

2.3           STUDY ASSUMPTIONS  41

2.4           RISK ANALYSIS  41

2.5           RESEARCH LIMITATIONS             42

2.5.1        METHODOLOGY-RELATED LIMITATIONS           42

2.5.2        SCOPE-RELATED LIMITATIONS                 42

3               EXECUTIVE SUMMARY  43

4               PREMIUM INSIGHTS       47

4.1           SMART PILLS MARKET OVERVIEW           47

4.2           NORTH AMERICA: SMART PILLS MARKET, BY APPLICATION AND COUNTRY, 2023         48

4.3           SMART PILLS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES              49

4.4           SMART PILLS MARKET: REGIONAL MIX 49

4.5           SMART PILLS MARKET: DEVELOPED VS. EMERGING MARKETS             50

5               MARKET OVERVIEW       51

5.1           INTRODUCTION              51

5.2           MARKET DYNAMICS       51

5.2.1        DRIVERS               52

5.2.1.1    Rising demand for non-invasive diagnostic monitoring devices                 52

5.2.1.2    Technological advancements in capsule endoscopy        53

5.2.1.3    Increasing incidence of colon cancer 54

5.2.2        RESTRAINTS      54

5.2.2.1    High R&D costs for technological developments and advancements        54

5.2.2.2    Low accuracy and reliability of sensors and cameras in smart pills                 55

5.2.3        OPPORTUNITIES              55

5.2.3.1    Innovations in sensor technologies and wireless communication                 55

5.2.3.2    Rising need for rapid drug delivery and development    55

5.2.4        CHALLENGES    56

5.2.4.1    Increased patient privacy and data security concerns     56

5.2.4.2    Shortage of skilled healthcare professionals     57

5.3           INDUSTRY TRENDS         58

5.3.1        ADVANCEMENTS IN SENSOR TECHNOLOGIES   58

5.3.2        INTEGRATION WITH AI AND ML               58

5.3.3        INTEGRATION WITH WEARABLE DEVICES           58

5.4           TECHNOLOGY ANALYSIS             59

5.4.1        KEY TECHNOLOGIES     59

5.4.1.1    Wireless communication systems      59

5.4.1.2    Sensor technologies              59

5.4.1.3    Self-powered ingestible smart pills    60

5.4.1.4    Adaptive frame rate technologies       60

5.4.1.5    iMAG     61

5.4.1.6    AI and ML              62

5.4.2        COMPLEMENTARY TECHNOLOGIES       62

5.4.2.1    Robotic technologies            62

5.4.2.2    Data analytics        63

5.4.3        ADJACENT TECHNOLOGIES       63

5.4.3.1    IoT          63

5.4.3.2    Cloud computing  63

5.5           TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS            63

5.6           PIPELINE ANALYSIS        64

5.7           PORTER’S FIVE FORCES ANALYSIS           66

5.7.1        INTENSITY OF COMPETITIVE RIVALRY 67

5.7.2        THREAT OF NEW ENTRANTS      67

5.7.3        THREAT OF SUBSTITUTES          68

5.7.4        BARGAINING POWER OF SUPPLIERS       68

5.7.5        BARGAINING POWER OF BUYERS             68

5.8           KEY STAKEHOLDERS & BUYING CRITERIA            69

5.8.1        KEY STAKEHOLDERS IN BUYING PROCESS           69

5.8.2        KEY BUYING CRITERIA  69

5.9           ECOSYSTEM ANALYSIS  70

5.10         VALUE CHAIN ANALYSIS               71

5.11         TARIFF & REGULATORY ANALYSIS           72

5.11.1      TARIFF DATA ANALYSIS                72

5.11.2      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             72

5.11.3      REGULATORY LANDSCAPE         74

5.11.3.1  North America      74

5.11.3.1.1                US           74

5.11.3.2  Europe   75

5.11.3.3  Asia Pacific            75

5.11.3.3.1                Japan      75

5.11.3.3.2                China      76

5.11.3.3.3                India       77

5.12         PRICING ANALYSIS          78

5.12.1      AVERAGE SELLING PRICE OF SMART PILLS, BY KEY PLAYER, 2023      78

5.12.2      AVERAGE SELLING PRICE TREND FOR CAPSULE ENDOSCOPES, BY REGION, 2020–2023      79

5.13         CASE STUDY ANALYSIS 79

5.13.1      INCREASED IMAGING CAPABILITIES FOR PATIENTS WITH SMALL BOWEL ABNORMALITIES 79

5.13.2      DETECTION OF GASTRIC POLYP & ERYTHEMA THROUGH MAGNETICALLY CONTROLLED CAPSULE ENDOSCOPES   80

5.13.3      AI-ASSISTED CAPSULE ENDOSCOPY TO DETECT OBSCURE GASTROINTESTINAL BLEEDING IN HIGH-RISK CARDIAC PATIENTS       80

5.14         PATENT ANALYSIS          81

5.14.1      PATENT PUBLICATION TRENDS FOR SMART PILLS                 81

5.14.2      INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS            82

5.14.3      LIST OF KEY PATENTS   83

5.15         KEY CONFERENCES & EVENTS, 2025–2026              84

5.16         UNMET NEEDS & END-USER EXPECTATIONS     85

5.16.1      UNMET NEEDS 85

5.16.2      END-USER EXPECTATIONS         86

5.17         TRADE ANALYSIS             87

5.18         INVESTMENT & FUNDING SCENARIO     88

5.19         BUSINESS MODEL ANALYSIS      88

5.19.1      DIRECT SALES TO HEALTHCARE PROVIDERS     88

5.19.2      SUBSCRIPTION-BASED SOFTWARE AND DATA ANALYTICS SERVICES    88

5.20         IMPACT OF AI/GEN AI ON SMART PILLS MARKET                 88

5.20.1      KEY USE CASES 90

5.20.2      CASE STUDIES OF AI/GEN AI IMPLEMENTATION                 90

5.20.2.1  CapsoCam SV-1 Versus PillCam SB3 to detect obscure gastrointestinal bleeding     90

5.20.2.2  AARDEX Group partnered with etectRx, Inc. to track medication-taking behaviors               91

5.20.3      IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS              92

5.20.3.1  AI in endoscopy    92

5.20.3.2  Wearable devices  92

5.20.3.3  Digital healthcare 93

5.20.3.4  Home healthcare  93

5.20.4      USER READINESS & IMPACT ASSESSMENT            93

5.20.4.1  User readiness       93

5.20.4.1.1                User A: Hospitals 93

5.20.4.1.2                User B: Diagnostic centers 93

5.20.4.2  Impact assessment                94

5.20.4.2.1                User A: Hospitals 94

5.20.4.2.1.1            Implementation    94

5.20.4.2.1.2            Impact    94

5.20.4.2.2                User B: Diagnostic centers 94

5.20.4.2.2.1            Implementation    94

5.20.4.2.2.2            Impact    95

6               SMART PILLS MARKET, BY TARGET AREA             96

6.1           INTRODUCTION              97

6.2           SMALL INTESTINE           97

6.2.1        COMPLEXITIES IN DIAGNOSIS AND MONITORING OF SMALL INTESTINE

TO AID ADOPTION OF SMART PILLS      97

6.3           LARGE INTESTINE           98

6.3.1        INCREASING INCIDENCE OF COLORECTAL CANCER TO SUPPORT MARKET GROWTH     98

6.4           ESOPHAGUS      99

6.4.1        HIGH PREVALENCE OF GASTROESOPHAGEAL REFLUX DISEASE AND BARRETT’S ESOPHAGUS TO AUGMENT MARKET GROWTH             99

6.5           STOMACH           100

6.5.1        IMPROVED DIAGNOSTIC ACCURACY AND EFFECTIVE PROXIMAL EXAMINATION SCOPE OF GASTRIC DISEASES TO DRIVE MARKET 100

7               SMART PILLS MARKET, BY APPLICATION             102

7.1           INTRODUCTION              103

7.2           CAPSULE ENDOSCOPY 103

7.2.1        INCREASED ABILITY TO ASSESS GASTROINTESTINAL BLEEDING AND SMALL BOWEL TUMORS TO DRIVE MARKET                 103

7.3           PATIENT MONITORING                105

7.3.1        NEED FOR STREAMLINED INTEGRATION OF INNOVATIVE SENSOR TECHNOLOGIES TO DRIVE MARKET                 105

7.4           TARGETED DRUG DELIVERY      106

7.4.1        SITE-SPECIFIC DRUG DELIVERY TO MINIMIZE DRUG DOSAGE

AND REDUCE HEALTHCARE COSTS        106

8               SMART PILLS MARKET, BY DISEASE INDICATION                 108

8.1           INTRODUCTION              109

8.2           OCCULT GASTROINTESTINAL BLEEDING            109

8.2.1        IMPROVED DIAGNOSTIC ACCURACY TO FUEL UPTAKE OF SMART PILLS AS PATIENT-FRIENDLY ALTERNATIVE                 109

8.3           CROHN’S DISEASE           110

8.3.1        TECHNOLOGICAL ADVANCEMENTS IN CAPSULE ENDOSCOPY TO BOOST ADOPTION OF SMART PILLS    110

8.4           CELIAC DISEASE               111

8.4.1        RISING INCIDENCE OF SMALL INTESTINE DISORDERS TO DRIVE MARKET         111

8.5           SMALL BOWEL TUMORS               112

8.5.1        GROWING DEMAND FOR NON-INVASIVE DIAGNOSTICS TO PROPEL MARKET GROWTH 112

8.6           OTHER DISEASE INDICATIONS 112

9               SMART PILLS MARKET, BY END USER     114

9.1           INTRODUCTION              115

9.2           HOSPITALS         115

9.2.1        INCREASING PREVALENCE OF INFLAMMATORY BOWEL DISEASE TO BOOST ADOPTION OF SMART PILLS IN HOSPITALS                 115

9.3           DIAGNOSTIC CENTERS 116

9.3.1        BETTER PATIENT EXPERIENCE AND IMPROVED OPERATIONAL EFFICIENCY TO BOOST MARKET GROWTH                 116

9.4           OUTPATIENT SETTINGS               117

9.4.1        NEED FOR ACCESSIBLE AND COST-EFFECTIVE CARE

TO SPUR MARKET GROWTH       117

9.5           OTHER END USERS         118

10            SMART PILLS MARKET, BY REGION         120

10.1         INTRODUCTION              121

10.2         NORTH AMERICA             122

10.2.1      MACROECONOMIC OUTLOOK FOR NORTH AMERICA                 123

10.2.2      US           125

10.2.2.1  US to dominate North American smart pills market

during study period              125

10.2.3      CANADA               128

10.2.3.1  Rising incidence of IBD among geriatric population to

propel market growth           128

10.3         EUROPE               130

10.3.1      MACROECONOMIC OUTLOOK FOR EUROPE      130

10.3.2      GERMANY           132

10.3.2.1  Rising prevalence of Crohn’s disease to aid market growth                 132

10.3.3      UK          134

10.3.3.1  Increasing prevalence of bowel cancer and colitis to

augment market growth      134

10.3.4      FRANCE                136

10.3.4.1  Favorable reimbursement coverage by government and third-party payers to aid market growth     136

10.3.5      ITALY    138

10.3.5.1  Growing adoption of capsule endoscopy for gastrointestinal diseases to propel market growth       138

10.3.6      SPAIN    140

10.3.6.1  Rising demand for non-invasive diagnostics to fuel uptake of smart pills              140

10.3.7      REST OF EUROPE             142

10.4         ASIA PACIFIC     144

10.4.1      MACROECONOMIC OUTLOOK FOR ASIA PACIFIC                 145

10.4.2      JAPAN   147

10.4.2.1  Increased prevalence of stomach cancer and favorable reimbursement scenario for capsule endoscopy to drive market  147

10.4.3      CHINA  150

10.4.3.1  Increasing geriatric population and rising incidence of gastric cancer to boost market growth           150

10.4.4      INDIA    152

10.4.4.1  Rising incidence of IBD and growing adoption of capsule endoscopy to support market growth                 152

10.4.5      REST OF ASIA PACIFIC   154

10.5         LATIN AMERICA                156

10.5.1      MACROECONOMIC OUTLOOK FOR LATIN AMERICA                 157

10.5.2      BRAZIL 159

10.5.2.1  Favorable government policies and presence of universal health coverage to aid market growth            159

10.5.3      MEXICO                161

10.5.3.1  Increased cancer awareness and favorable government initiatives to drive market      161

10.5.4      REST OF LATIN AMERICA             163

10.6         MIDDLE EAST & AFRICA                164

10.6.1      MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 165

10.6.2      GCC COUNTRIES              167

10.6.2.1  Increased focus on healthcare infrastructure development and high R&D investment to support market growth             167

10.6.3      REST OF MIDDLE EAST & AFRICA             168

11            COMPETITIVE LANDSCAPE         171

11.1         INTRODUCTION              171

11.2         KEY PLAYER STRATEGIES/RIGHT TO WIN            171

11.2.1      OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN

SMART PILLS MARKET  171

11.3         REVENUE ANALYSIS, 2019–2023  174

11.4         MARKET SHARE ANALYSIS, 2023                 175

11.5         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023                 176

11.5.1      STARS   176

11.5.2      EMERGING LEADERS     176

11.5.3      PERVASIVE PLAYERS      176

11.5.4      PARTICIPANTS 176

11.5.5      COMPANY FOOTPRINT: KEY PLAYERS, 2023         178

11.5.5.1  Company footprint               178

11.5.5.2  Region footprint   179

11.5.5.3  Application footprint            180

11.5.5.4  Target area footprint            181

11.5.5.5  Disease indication footprint                181

11.5.5.6  End-user footprint                182

11.5.5.7  Region footprint   183

11.6         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023        183

11.6.1      PROGRESSIVE COMPANIES         183

11.6.2      RESPONSIVE COMPANIES            183

11.6.3      DYNAMIC COMPANIES  183

11.6.4      STARTING BLOCKS         184

11.6.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023                 185

11.6.5.1  Detailed list of key startups/SME players         185

11.6.5.2  Competitive benchmarking of key startups/SME players                 186

11.7         COMPANY VALUATION & FINANCIAL METRICS 187

11.7.1      FINANCIAL METRICS      187

11.7.2      COMPANY VALUATION 187

11.8         BRAND/PRODUCT COMPARISON             188

11.9         COMPETITIVE SCENARIO             189

11.9.1      PRODUCT LAUNCHES, APPROVALS, AND ENHANCEMENTS             189

11.9.2      DEALS  190

11.9.3      OTHER DEVELOPMENTS              191

12            COMPANY PROFILES      192

12.1         KEY PLAYERS     192

12.1.1      MEDTRONIC      192

12.1.1.1  Business overview 192

12.1.1.2  Products/Services/Solutions offered 193

12.1.1.3  Recent developments           194

12.1.1.3.1                Product approvals & enhancements  194

12.1.1.3.2                Deals      194

12.1.1.4  MnM view              195

12.1.1.4.1                Right to win           195

12.1.1.4.2                Strategic choices   195

12.1.1.4.3                Weaknesses & competitive threats     195

12.1.2      OLYMPUS CORPORATION           196

12.1.2.1  Business overview 196

12.1.2.2  Products/Services/Solutions offered 197

12.1.2.3  Recent developments           198

12.1.2.3.1                Other developments             198

12.1.2.4  MnM view              198

12.1.2.4.1                Right to win           198

12.1.2.4.2                Strategic choices   198

12.1.2.4.3                Weaknesses & competitive threats     198

12.1.3      CAPSOVISION, INC.         199

12.1.3.1  Business overview 199

12.1.3.2  Products/Services/Solutions offered 199

12.1.3.3  Recent developments           200

12.1.3.3.1                Product approvals & enhancements  200

12.1.3.4  MnM view              201

12.1.3.4.1                Right to win           201

12.1.3.4.2                Strategic choices   201

12.1.3.4.3                Weaknesses & competitive threats     201

12.1.4      INTROMEDIC    202

12.1.4.1  Business overview 202

12.1.4.2  Products/Services/Solutions offered 202

12.1.4.3  MnM view              203

12.1.4.3.1                Right to win           203

12.1.4.3.2                Strategic choices   203

12.1.4.3.3                Weaknesses & competitive threats     203

12.1.5      JINSHAN SCIENCE & TECHNOLOGY         204

12.1.5.1  Business overview 204

12.1.5.2  Products/Services/Solutions offered 204

12.1.5.3  MnM view              205

12.1.5.3.1                Right to win           205

12.1.5.3.2                Strategic choices   205

12.1.5.3.3                Weaknesses & competitive threats     205

12.1.6      ANX ROBOTICS 206

12.1.6.1  Business overview 206

12.1.6.2  Products/Services/Solutions offered 206

12.1.6.3  Recent developments           207

12.1.6.3.1                Product launches, approvals, and enhancements                 207

12.1.7      SHENZHEN JIFU MEDICAL TECHNOLOGY CO., LTD.                 208

12.1.7.1  Business overview 208

12.1.7.2  Products/Services/Solutions offered 208

12.1.8      ETECTRX             209

12.1.8.1  Business overview 209

12.1.8.2  Products/Services/Solutions offered 209

12.1.8.3  Recent developments           210

12.1.8.3.1                Product enhancements        210

12.1.8.3.2                Deals      210

12.1.9      BODYCAP            211

12.1.9.1  Business overview 211

12.1.9.2  Products/Services/Solutions offered 211

12.1.9.3  Recent developments           212

12.1.9.3.1                Product launches  212

12.1.9.3.2                Deals      212

12.1.10   CHECK-CAP        213

12.1.10.1                 Business overview 213

12.1.10.2                 Products/Services/Solutions offered 213

12.1.10.3                 Recent developments           214

12.1.10.3.1             Product approvals 214

12.1.10.3.2             Expansions             214

12.1.11   SHANGXIAN MINIMAL INVASIVE INC.     215

12.1.11.1                 Business overview 215

12.1.11.2                 Products/Services/Solutions offered 215

12.2         OTHER PLAYERS              216

12.2.1      VELOCE CORPORATION               216

12.2.2      BIOCAM               216

12.2.3      ENDIATX             217

12.2.4      RF CO., LTD.       217

12.2.5      CELERO SYSTEMS            218

12.2.6      BIORA THERAPEUTICS, INC.       218

12.2.7      INNURVATION 219

12.2.8      RANI THERAPEUTICS     220

12.2.9      MOTILIS MEDICA SA      221

13            APPENDIX           222

13.1         DISCUSSION GUIDE        222

13.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                226

13.3         CUSTOMIZATION OPTIONS        228

13.4         RELATED REPORTS         228

13.5         AUTHOR DETAILS           229

LIST OF TABLES

TABLE 1                SMART PILLS MARKET: INCLUSIONS & EXCLUSIONS      27

TABLE 2                SMART PILLS MARKET: STUDY ASSUMPTIONS                 41

TABLE 3                SMART PILLS MARKET: RISK ANALYSIS  41

TABLE 4                SMART PILLS MARKET: IMPACT ANALYSIS                 52

TABLE 5                SENSOR AND BATTERY TYPES FOR CAPSULE ENDOSCOPY PRODUCTS              61

TABLE 6                SENSORS USED FOR VITAL SIGN MONITORING PRODUCTS         62

TABLE 7                SMART PILLS MARKET: DRUGS UNDER PIPELINE             64

TABLE 8                SMART PILLS MARKET: PORTER’S FIVE FORCES ANALYSIS            66

TABLE 9                INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY APPLICATION (%)               69

TABLE 10              KEY BUYING CRITERIA FOR SMART PILLS, BY APPLICATION   70

TABLE 11              TARIFF DATA FOR HS CODE 901890          72

TABLE 12              NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  72

TABLE 13              EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  73

TABLE 14              ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  73

TABLE 15              US FDA: MEDICAL DEVICE CLASSIFICATION                 74

TABLE 16              US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS              74

TABLE 17              EUROPE: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF

REGISTRATION PROCESS             75

TABLE 18              JAPAN: MEDICAL DEVICES CLASSIFICATION UNDER PMDA   76

TABLE 19              CHINA: CLASSIFICATION UNDER CLASS I/II/III MEDICAL DEVICES          76

TABLE 20              INDIA: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS         77

TABLE 21              AVERAGE SELLING PRICE OF CAPSULE ENDOSCOPES, BY KEY PLAYER, 2023 (USD)          78

TABLE 22              AVERAGE SELLING PRICE TREND OF CAPSULE ENDOSCOPES, BY REGION, 2020–2023 (USD PER UNIT)   79

TABLE 23              CASE STUDY 1: INCREASED IMAGING CAPABILITIES FOR PATIENTS WITH SMALL BOWEL ABNORMALITIES              79

TABLE 24              CASE STUDY 2: DETECTION OF GASTRIC POLYP & ERYTHEMA THROUGH MAGNETICALLY CONTROLLED CAPSULE ENDOSCOPES                80

TABLE 25              CASE STUDY 3: AI-ASSISTED CAPSULE ENDOSCOPY TO DETECT OBSCURE GASTROINTESTINAL BLEEDING IN HIGH-RISK CARDIAC PATIENTS    80

TABLE 26              SMART PILLS MARKET: LIST OF KEY PATENTS, JANUARY 2020–DECEMBER 2024 83

TABLE 27              SMART PILLS MARKET: LIST OF KEY CONFERENCES & EVENTS,

JANUARY 2025–DECEMBER 2026 84

TABLE 28              SMART PILLS MARKET: UNMET NEEDS 85

TABLE 29              SMART PILLS MARKET: END-USER EXPECTATIONS                86

TABLE 30              TOP 10 IMPORTERS FOR HSN CODE 901890, BY COUNTRY,

2020−2023 (USD THOUSAND)    87

TABLE 31              TOP 10 EXPORTERS FOR HSN CODE 901890, BY COUNTRY,

2020−2023 (USD THOUSAND)    87

TABLE 32              CASE STUDY 1: CAPSOCAM SV-1 VERSUS PILLCAM SB3 TO DETECT OBSCURE GASTROINTESTINAL BLEEDING          90

TABLE 33              CASE STUDY 2: AARDEX GROUP PARTNERED WITH ETECTRX, INC. TO TRACK MEDICATION-TAKING BEHAVIORS        91

TABLE 34              SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION)       97

TABLE 35              SMART PILLS MARKET FOR SMALL INTESTINE, BY REGION,

2022–2030 (USD MILLION)            98

TABLE 36              SMART PILLS MARKET FOR LARGE INTESTINE, BY REGION,

2022–2030 (USD MILLION)            99

TABLE 37              SMART PILLS MARKET FOR ESOPHAGUS, BY REGION, 2022–2030 (USD MILLION)          100

TABLE 38              SMART PILLS MARKET FOR STOMACH, BY REGION, 2022–2030 (USD MILLION)          101

TABLE 39              SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)       103

TABLE 40              KEY CAPSULE ENDOSCOPES OFFERED BY MAJOR MARKET PLAYERS            104

TABLE 41              SMART PILLS MARKET FOR CAPSULE ENDOSCOPY, BY REGION,

2022–2030 (USD MILLION)            104

TABLE 42              KEY PATIENT MONITORING SMART PILLS OFFERED BY MAJOR MARKET PLAYERS 105

TABLE 43              SMART PILLS MARKET FOR PATIENT MONITORING, BY REGION,

2022–2030 (USD MILLION)            106

TABLE 44              KEY TARGETED DRUG DELIVERY SMART PILLS UNDER PIPELINE             107

TABLE 45              SMART PILLS MARKET FOR TARGETED DRUG DELIVERY, BY REGION,

2022–2030 (USD MILLION)            107

TABLE 46              SMART PILLS MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION)                109

TABLE 47              SMART PILLS MARKET FOR OCCULT GASTROINTESTINAL BLEEDING, BY REGION, 2022–2030 (USD MILLION)            110

TABLE 48              SMART PILLS MARKET FOR CROHN’S DISEASE, BY REGION,

2022–2030 (USD MILLION)            111

TABLE 49              SMART PILLS MARKET FOR CELIAC DISEASE, BY REGION,

2022–2030 (USD MILLION)            111

TABLE 50              SMART PILLS MARKET FOR SMALL BOWEL TUMORS, BY REGION,

2022–2030 (USD MILLION)            112

TABLE 51              SMART PILLS MARKET FOR OTHER DISEASE INDICATIONS, BY REGION,

2022–2030 (USD MILLION)            113

TABLE 52              SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION) 115

TABLE 53              SMART PILLS MARKET FOR HOSPITALS, BY REGION, 2022–2030 (USD MILLION)          116

TABLE 54              SMART PILLS MARKET FOR DIAGNOSTIC CENTERS, BY REGION,

2022–2030 (USD MILLION)            117

TABLE 55              SMART PILLS MARKET FOR OUTPATIENT SETTINGS, BY REGION,

2022–2030 (USD MILLION)            118

TABLE 56              SMART PILLS MARKET FOR OTHER END USERS, BY REGION,

2022–2030 (USD MILLION)            119

TABLE 57              SMART PILLS MARKET, BY REGION, 2022–2030 (USD MILLION) 121

TABLE 58              SMART PILLS MARKET FOR CAPSULE ENDOSCOPY, BY REGION,

2022–2030 (THOUSAND UNITS)  121

TABLE 59              SMART PILLS MARKET FOR PATIENT MONITORING, BY REGION,

2022–2030 (THOUSAND UNITS)  122

TABLE 60              NORTH AMERICA: SMART PILLS MARKET, BY COUNTRY,

2022–2030 (USD MILLION)            124

TABLE 61              NORTH AMERICA: SMART PILLS MARKET, BY TARGET AREA,

2022–2030 (USD MILLION)            124

TABLE 62              NORTH AMERICA: SMART PILLS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            124

TABLE 63              NORTH AMERICA: SMART PILLS MARKET, BY DISEASE INDICATION,

2022–2030 (USD MILLION)            125

TABLE 64              NORTH AMERICA: SMART PILLS MARKET, BY END USER,

2022–2030 (USD MILLION)            125

TABLE 65              US: KEY MACROINDICATORS     126

TABLE 66              US: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION)            127

TABLE 67              US: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)            127

TABLE 68              US: SMART PILLS MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION)                127

TABLE 69              US: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION)       128

TABLE 70              CANADA: KEY MACROINDICATORS         128

TABLE 71              CANADA: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION)               129

TABLE 72              CANADA: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)              129

TABLE 73              CANADA: SMART PILLS MARKET, BY DISEASE INDICATION,

2022–2030 (USD MILLION)            129

TABLE 74              CANADA: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION)            130

TABLE 75              EUROPE: SMART PILLS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)            131

TABLE 76              EUROPE: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION)               131

TABLE 77              EUROPE: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)              131

TABLE 78              EUROPE: SMART PILLS MARKET, BY DISEASE INDICATION,

2022–2030 (USD MILLION)            132

TABLE 79              EUROPE: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION)            132

TABLE 80              GERMANY: KEY MACROINDICATORS      133

TABLE 81              GERMANY: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION)               133

TABLE 82              GERMANY: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)              133

TABLE 83              GERMANY: SMART PILLS MARKET, BY DISEASE INDICATION,

2022–2030 (USD MILLION)            134

TABLE 84             GERMANY: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION)            134

TABLE 85              UK: KEY MACROINDICATORS     135

TABLE 86              UK: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION)            135

TABLE 87              UK: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)            135

TABLE 88              UK: SMART PILLS MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION)                136

TABLE 89              UK: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION)       136

TABLE 90              FRANCE: KEY MACROINDICATORS          137

TABLE 91              FRANCE: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION)               137

TABLE 92              FRANCE: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)              137

TABLE 93              FRANCE: SMART PILLS MARKET, BY DISEASE INDICATION,

2022–2030 (USD MILLION)            138

TABLE 94              FRANCE: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION)            138

TABLE 95              ITALY: KEY MACROINDICATORS               139

TABLE 96             ITALY: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION)            139

TABLE 97             ITALY: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)            139

TABLE 98              ITALY: SMART PILLS MARKET, BY DISEASE INDICATION,

2022–2030 (USD MILLION)            140

TABLE 99              ITALY: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION)            140

TABLE 100            SPAIN: KEY MACROINDICATORS               141

TABLE 101          SPAIN: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION)            141

TABLE 102          SPAIN: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)            141

TABLE 103            SPAIN: SMART PILLS MARKET, BY DISEASE INDICATION,

2022–2030 (USD MILLION)            142

TABLE 104            SPAIN: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION)            142

TABLE 105            REST OF EUROPE: SMART PILLS MARKET, BY TARGET AREA,

2022–2030 (USD MILLION)            143

TABLE 106            REST OF EUROPE: SMART PILLS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            143

TABLE 107            REST OF EUROPE: SMART PILLS MARKET, BY DISEASE INDICATION,

2022–2030 (USD MILLION)            143

TABLE 108            REST OF EUROPE: SMART PILLS MARKET, BY END USER,

2022–2030 (USD MILLION)            144

TABLE 109            ASIA PACIFIC: SMART PILLS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)     146

TABLE 110            ASIA PACIFIC: SMART PILLS MARKET, BY TARGET AREA,

2022–2030 (USD MILLION)            146

TABLE 111            ASIA PACIFIC: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)              146

TABLE 112            ASIA PACIFIC: SMART PILLS MARKET, BY DISEASE INDICATION,

2022–2030 (USD MILLION)            147

TABLE 113            ASIA PACIFIC: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION)                147

TABLE 114            JAPAN: KEY MACROINDICATORS              148

TABLE 115            JAPAN: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION)               148

TABLE 116          JAPAN: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)            149

TABLE 117            JAPAN: SMART PILLS MARKET, BY DISEASE INDICATION,

2022–2030 (USD MILLION)            149

TABLE 118            JAPAN: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION)            149

TABLE 119            CHINA: KEY MACROINDICATORS             150

TABLE 120            CHINA: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION)               151

TABLE 121            CHINA: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)              151

TABLE 122            CHINA: SMART PILLS MARKET, BY DISEASE INDICATION,

2022–2030 (USD MILLION)            151

TABLE 123            CHINA: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION)            152

TABLE 124            INDIA: KEY MACROINDICATORS               153

TABLE 125          INDIA: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION)            153

TABLE 126          INDIA: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)            153

TABLE 127            INDIA: SMART PILLS MARKET, BY DISEASE INDICATION,

2022–2030 (USD MILLION)            154

TABLE 128            INDIA: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION)            154

TABLE 129            REST OF ASIA PACIFIC: SMART PILLS MARKET, BY TARGET AREA,

2022–2030 (USD MILLION)            155

TABLE 130            REST OF ASIA PACIFIC: SMART PILLS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            155

TABLE 131            REST OF ASIA PACIFIC: SMART PILLS MARKET, BY DISEASE INDICATION,

2022–2030 (USD MILLION)            156

TABLE 132            REST OF ASIA PACIFIC: SMART PILLS MARKET, BY END USER,

2022–2030 (USD MILLION)            156

TABLE 133            LATIN AMERICA: SMART PILLS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)     157

TABLE 134            LATIN AMERICA: SMART PILLS MARKET, BY TARGET AREA,

2022–2030 (USD MILLION)            157

TABLE 135            LATIN AMERICA: SMART PILLS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            158

TABLE 136            LATIN AMERICA: SMART PILLS MARKET, BY DISEASE INDICATION,

2022–2030 (USD MILLION)            158

TABLE 137            LATIN AMERICA: SMART PILLS MARKET, BY END USER,

2022–2030 (USD MILLION)            158

TABLE 138            BRAZIL: KEY MACROINDICATORS            159

TABLE 139            BRAZIL: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION)               159

TABLE 140            BRAZIL: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)              160

TABLE 141            BRAZIL: SMART PILLS MARKET, BY DISEASE INDICATION,

2022–2030 (USD MILLION)            160

TABLE 142            BRAZIL: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION)            160

TABLE 143            MEXICO: KEY MACROINDICATORS          161

TABLE 144            MEXICO: SMART PILLS MARKET, BY TARGET AREA, 2022–2030 (USD MILLION)               161

TABLE 145            MEXICO: SMART PILLS MARKET, BY APPLICATION, 2022–2030 (USD MILLION)              162

TABLE 146            MEXICO: SMART PILLS MARKET, BY DISEASE INDICATION,

2022–2030 (USD MILLION)            162

TABLE 147            MEXICO: SMART PILLS MARKET, BY END USER, 2022–2030 (USD MILLION)            162

TABLE 148            REST OF LATIN AMERICA: SMART PILLS MARKET, BY TARGET AREA,

2022–2030 (USD MILLION)            163

TABLE 149            REST OF LATIN AMERICA: SMART PILLS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            163

TABLE 150            REST OF LATIN AMERICA: SMART PILLS MARKET, BY DISEASE INDICATION,

2022–2030 (USD MILLION)            164

TABLE 151            REST OF LATIN AMERICA: SMART PILLS MARKET, BY END USER,

2022–2030 (USD MILLION)            164

TABLE 152            MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY REGION,

2022–2030 (USD MILLION)            165

TABLE 153            MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY TARGET AREA,

2022–2030 (USD MILLION)            165

TABLE 154            MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            166

TABLE 155            MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY DISEASE INDICATION,

2022–2030 (USD MILLION)            166

TABLE 156            MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY END USER,

2022–2030 (USD MILLION)            166

TABLE 157            GCC COUNTRIES: SMART PILLS MARKET, BY TARGET AREA,

2022–2030 (USD MILLION)            167

TABLE 158            GCC COUNTRIES: SMART PILLS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            167

TABLE 159            GCC COUNTRIES: SMART PILLS MARKET, BY DISEASE INDICATION,

2022–2030 (USD MILLION)            168

TABLE 160            GCC COUNTRIES: SMART PILLS MARKET, BY END USER,

2022–2030 (USD MILLION)            168

TABLE 161            REST OF MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY TARGET AREA,

2022–2030 (USD MILLION)            169

TABLE 162            REST OF MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            169

TABLE 163            REST OF MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY DISEASE INDICATION, 2022–2030 (USD MILLION)                 169

TABLE 164            REST OF MIDDLE EAST & AFRICA: SMART PILLS MARKET, BY END USER,

2022–2030 (USD MILLION)            170

TABLE 165            OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN SMART PILLS MARKET, JANUARY 2021–JANUARY 2025        171

TABLE 166            SMART PILLS MARKET: DEGREE OF COMPETITION 175

TABLE 167            SMART PILLS MARKET: REGION FOOTPRINT                 179

TABLE 168            SMART PILLS MARKET: APPLICATION FOOTPRINT       180

TABLE 169            SMART PILLS MARKET: TARGET AREA FOOTPRINT       181

TABLE 170            SMART PILLS MARKET: DISEASE INDICATION FOOTPRINT       181

TABLE 171            SMART PILLS MARKET: END-USER FOOTPRINT                 182

TABLE 172            SMART PILLS MARKET: REGION FOOTPRINT                 183

TABLE 173            SMART PILLS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS             185

TABLE 174            SMART PILLS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS         186

TABLE 175            SMART PILLS MARKET: PRODUCT LAUNCHES, APPROVALS, AND ENHANCEMENTS, JANUARY 2021–JANUARY 2025        189

TABLE 176            SMART PILLS MARKET: DEALS, JANUARY 2021–JANUARY 2025    190

TABLE 177            SMART PILLS MARKET: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025                 191

TABLE 178            MEDTRONIC: COMPANY OVERVIEW       192

TABLE 179            MEDTRONIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED    193

TABLE 180            MEDTRONIC: PRODUCT APPROVALS & ENHANCEMENTS,

JANUARY 2021–JANUARY 2025     194

TABLE 181            MEDTRONIC: DEALS, JANUARY 2021–JANUARY 2025        194

TABLE 182            OLYMPUS CORPORATION: COMPANY OVERVIEW          196

TABLE 183            OLYMPUS CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED    197

TABLE 184            OLYMPUS CORPORATION: OTHER DEVELOPMENTS,

JANUARY 2021–JANUARY 2025     198

TABLE 185            CAPSOVISION, INC.: COMPANY OVERVIEW                 199

TABLE 186            CAPSOVISION, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED    199

TABLE 187            CAPSOVISION, INC.: PRODUCT APPROVALS & ENHANCEMENTS, JANUARY 2021–JANUARY 2025                200

TABLE 188            INTROMEDIC: COMPANY OVERVIEW     202

TABLE 189            INTROMEDIC: PRODUCTS/SERVICES/SOLUTIONS OFFERED    202

TABLE 190            JINSHAN SCIENCE & TECHNOLOGY: COMPANY OVERVIEW          204

TABLE 191            JINSHAN SCIENCE & TECHNOLOGY: PRODUCTS/SERVICES/SOLUTIONS OFFERED    204

TABLE 192            ANX ROBOTICS: COMPANY OVERVIEW 206

TABLE 193            ANX ROBOTICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED    206

TABLE 194            ANX ROBOTICS: PRODUCT LAUNCHES, APPROVALS, AND ENHANCEMENTS, JANUARY 2021–JANUARY 2025        207

TABLE 195            SHENZHEN JIFU MEDICAL TECHNOLOGY CO., LTD.: COMPANY OVERVIEW       208

TABLE 196            SHENZHEN JIFU MEDICAL TECHNOLOGY CO., LTD.: PRODUCTS/SERVICES/ SOLUTIONS OFFERED       208

TABLE 197            ETECTRX: COMPANY OVERVIEW              209

TABLE 198            ETECTRX: PRODUCTS/SERVICES/SOLUTIONS OFFERED             209

TABLE 199            ETECTRX: PRODUCT ENHANCEMENTS, JANUARY 2021–JANUARY 2025     210

TABLE 200            ETECTRX: DEALS, JANUARY 2021–JANUARY 2025                 210

TABLE 201            BODYCAP: COMPANY OVERVIEW             211

TABLE 202            BODYCAP: PRODUCTS/SERVICES/SOLUTIONS OFFERED             211

TABLE 203            BODYCAP: PRODUCT LAUNCHES, JANUARY 2021–JANUARY 2025         212

TABLE 204            BODYCAP: DEALS, JANUARY 2021–JANUARY 2025                 212

TABLE 205            CHECK-CAP: COMPANY OVERVIEW        213

TABLE 206            CHECK-CAP: PRODUCTS/SERVICES/SOLUTIONS OFFERED    213

TABLE 207            CHECK-CAP: PRODUCT APPROVALS, JANUARY 2021–JANUARY 2025         214

TABLE 208            CHECK-CAP: EXPANSIONS, JANUARY 2021–JANUARY 2025    214

TABLE 209            SHANGXIAN MINIMAL INVASIVE INC.: COMPANY OVERVIEW   215

TABLE 210            SHANGXIAN MINIMAL INVASIVE INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED    215

TABLE 211            VELOCE CORPORATION: COMPANY OVERVIEW                 216

TABLE 212            BIOCAM: COMPANY OVERVIEW                216

TABLE 213            ENDIATX: COMPANY OVERVIEW              217

TABLE 214            RF CO., LTD.: COMPANY OVERVIEW       217

TABLE 215            CELERO SYSTEMS: COMPANY OVERVIEW                 218

TABLE 216            BIORA THERAPEUTICS, INC.: COMPANY OVERVIEW          218

TABLE 217            INNURVATION: COMPANY OVERVIEW  219

TABLE 218            RANI THERAPEUTICS: COMPANY OVERVIEW                 220

TABLE 219            MOTILIS MEDICA SA: COMPANY OVERVIEW                 221

LIST OF FIGURES

FIGURE 1              SMART PILLS MARKET SEGMENTATION & GEOGRAPHICAL SPREAD             26

FIGURE 2              SMART PILLS MARKET: YEARS CONSIDERED                 28

FIGURE 3              SMART PILLS MARKET: RESEARCH DESIGN                 30

FIGURE 4              SMART PILLS MARKET: KEY DATA FROM SECONDARY SOURCES  31

FIGURE 5              SMART PILLS MARKET: KEY PRIMARY SOURCES                 32

FIGURE 6              SMART PILLS MARKET: KEY DATA FROM PRIMARY SOURCES         33

FIGURE 7              SMART PILLS MARKET: INSIGHTS FROM KEY PRIMARIES          33

FIGURE 8              BREAKDOWN OF PRIMARY EXPERTS: BY COMPANY TYPE,

DESIGNATION, AND REGION     34

FIGURE 9              MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS            35

FIGURE 10            SMART PILLS MARKET: BOTTOM-UP APPROACH (DEMAND-SIDE ANALYSIS) 36

FIGURE 11            SMART PILLS MARKET: TOP-DOWN APPROACH                 36

FIGURE 12            SMART PILLS MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2024–2030)  38

FIGURE 13            SMART PILLS MARKET: CAGR PROJECTIONS (SUPPLY SIDE)  38

FIGURE 14            SMART PILLS MARKET: DATA TRIANGULATION                 40

FIGURE 15            SMART PILLS MARKET, BY APPLICATION, 2024 VS. 2030 (USD MILLION)                43

FIGURE 16            SMART PILLS MARKET, BY TARGET AREA, 2024 VS. 2030 (USD MILLION)                44

FIGURE 17            SMART PILLS MARKET, BY DISEASE INDICATION, 2024 VS. 2030 (USD MILLION)          44

FIGURE 18            SMART PILLS MARKET, BY END USER, 2024 VS. 2030 (USD MILLION)       45

FIGURE 19            REGIONAL SNAPSHOT OF SMART PILLS MARKET               45

FIGURE 20            INCREASING ADOPTION OF CAPSULE ENDOSCOPY IN EMERGING

ECONOMIES TO FUEL UPTAKE OF SMART PILLS               47

FIGURE 21            US AND CAPSULE ENDOSCOPY SEGMENTS DOMINATED NORTH AMERICAN SMART PILLS MARKET IN 2023                 48

FIGURE 22            CHINA TO REGISTER HIGHEST GROWTH RATE FROM 2024 TO 2030          49

FIGURE 23            ASIA PACIFIC TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD       49

FIGURE 24            EMERGING MARKETS TO REGISTER HIGHEST

GROWTH RATE DURING STUDY PERIOD              50

FIGURE 25            SMART PILLS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES     51

FIGURE 26            HEALTHCARE SECURITY BREACHES OF 500 + RECORDS, 2009–2024       57

FIGURE 27            SMART PILLS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS      63

FIGURE 28            SMART PILLS MARKET: PORTER’S FIVE FORCES ANALYSIS            67

FIGURE 29            INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY APPLICATION       69

FIGURE 30            KEY BUYING CRITERIA FOR SMART PILLS, BY APPLICATION   69

FIGURE 31            SMART PILLS MARKET: ECOSYSTEM ANALYSIS                 70

FIGURE 32            SMART PILLS MARKET: VALUE CHAIN ANALYSIS                 71

FIGURE 33            AVERAGE SELLING PRICE OF SMART PILLS, BY KEY PLAYER (2023)           78

FIGURE 34            SMART PILLS MARKET: GLOBAL PATENT PUBLICATION TRENDS (2015–2024)          81

FIGURE 35            TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR SMART PILL PATENTS (JANUARY 2014–DECEMBER 2024)              82

FIGURE 36            TOP APPLICANTS FOR SMART PILL PATENTS (COUNTRY/REGION)

(JANUARY 2014–DECEMBER 2024)              83

FIGURE 37            SMART PILLS MARKET: FUNDING AND NUMBER OF DEALS (2020–2024)     88

FIGURE 38            MARKET POTENTIAL OF AI/GEN AI ON SMART PILLS ACROSS INDUSTRIES         89

FIGURE 39            IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS   92

FIGURE 40            NORTH AMERICA: SMART PILLS MARKET SNAPSHOT          123

FIGURE 41            ASIA PACIFIC: SMART PILLS MARKET SNAPSHOT          145

FIGURE 42            REVENUE ANALYSIS OF KEY PLAYERS IN SMART PILLS MARKET,

2019–2023 (USD MILLION)            174

FIGURE 43            MARKET SHARE ANALYSIS OF KEY PLAYERS IN SMART PILLS MARKET (2023)      175

FIGURE 44            SMART PILLS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023         177

FIGURE 45            SMART PILLS MARKET: COMPANY FOOTPRINT                 178

FIGURE 46            SMART PILLS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 184

FIGURE 47            EV/EBITDA OF KEY VENDORS   187

FIGURE 48            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA

OF KEY VENDORS            187

FIGURE 49            SMART PILLS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS            188

FIGURE 50            MEDTRONIC: COMPANY SNAPSHOT      193

FIGURE 51            OLYMPUS CORPORATION: COMPANY SNAPSHOT          197

MarketsandMarkets（マーケッツアンドマーケッツ）は広範な市場を対象にした市場調査レポートを出版しています。世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• コンクリートシーラー市場 – 2030年までの世界予測 2025-04-21
• 自動車用ヒートシールド市場 – 2032年までの世界予測 2025-04-21
• XEVアフターマーケットの進化に関する競争力情報 – 2035年までの世界予測 2025-04-17
• アプリケーションライフサイクル管理市場 – 2029年までの世界予測 2025-04-17
• ヒンダードアミン光安定剤（HALS）市場 – 2030年までの世界予測 2025-04-17

MarketsandMarkets  出版レポート一覧